210 related articles for article (PubMed ID: 35027560)
21. Ductal Carcinoma In Situ of Breast: From Molecular Etiology to Therapeutic Management.
Hophan SL; Odnokoz O; Liu H; Luo Y; Khan S; Gradishar W; Zhou Z; Badve S; Torres MA; Wan Y
Endocrinology; 2022 Apr; 163(4):. PubMed ID: 35245349
[TBL] [Abstract][Full Text] [Related]
22. Loss of heterozygosity analyses of asynchronous lesions of ductal carcinoma in situ and invasive ductal carcinoma of the human breast.
Amari M; Moriya T; Ishida T; Harada Y; Ohnuki K; Takeda M; Sasano H; Horii A; Ohuchi N
Jpn J Clin Oncol; 2003 Nov; 33(11):556-62. PubMed ID: 14711979
[TBL] [Abstract][Full Text] [Related]
23. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution.
Allred DC; Wu Y; Mao S; Nagtegaal ID; Lee S; Perou CM; Mohsin SK; O'Connell P; Tsimelzon A; Medina D
Clin Cancer Res; 2008 Jan; 14(2):370-8. PubMed ID: 18223211
[TBL] [Abstract][Full Text] [Related]
24. Subtype-specific micro-RNA expression signatures in breast cancer progression.
Haakensen VD; Nygaard V; Greger L; Aure MR; Fromm B; Bukholm IR; Lüders T; Chin SF; Git A; Caldas C; Kristensen VN; Brazma A; Børresen-Dale AL; Hovig E; Helland Å
Int J Cancer; 2016 Sep; 139(5):1117-28. PubMed ID: 27082076
[TBL] [Abstract][Full Text] [Related]
25. Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model.
Maguire SL; Peck B; Wai PT; Campbell J; Barker H; Gulati A; Daley F; Vyse S; Huang P; Lord CJ; Farnie G; Brennan K; Natrajan R
J Pathol; 2016 Nov; 240(3):315-328. PubMed ID: 27512948
[TBL] [Abstract][Full Text] [Related]
26. Genomic Alterations during the
Trinh A; Gil Del Alcazar CR; Shukla SA; Chin K; Chang YH; Thibault G; Eng J; Jovanović B; Aldaz CM; Park SY; Jeong J; Wu C; Gray J; Polyak K
Mol Cancer Res; 2021 Apr; 19(4):623-635. PubMed ID: 33443130
[TBL] [Abstract][Full Text] [Related]
27. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
28. In microdissected ductal carcinoma in situ, HER-2/neu amplification, but not p53 mutation, is associated with high nuclear grade and comedo histology.
Ho GH; Calvano JE; Bisogna M; Borgen PI; Rosen PP; Tan LK; Van Zee KJ
Cancer; 2000 Dec; 89(11):2153-60. PubMed ID: 11147584
[TBL] [Abstract][Full Text] [Related]
29. Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer.
Bergholtz H; Kumar S; Wärnberg F; Lüders T; Kristensen V; Sørlie T
Cancer Rep (Hoboken); 2020 Jun; 3(3):e1248. PubMed ID: 32671987
[TBL] [Abstract][Full Text] [Related]
30. Patterns of chromosomal alterations in breast ductal carcinoma in situ.
Hwang ES; DeVries S; Chew KL; Moore DH; Kerlikowske K; Thor A; Ljung BM; Waldman FM
Clin Cancer Res; 2004 Aug; 10(15):5160-7. PubMed ID: 15297420
[TBL] [Abstract][Full Text] [Related]
31. Ductal carcinoma in situ of the breast: the importance of morphologic and molecular interactions.
Mardekian SK; Bombonati A; Palazzo JP
Hum Pathol; 2016 Mar; 49():114-23. PubMed ID: 26826418
[TBL] [Abstract][Full Text] [Related]
32. Genetic divergence in the clonal evolution of breast cancer.
Fujii H; Marsh C; Cairns P; Sidransky D; Gabrielson E
Cancer Res; 1996 Apr; 56(7):1493-7. PubMed ID: 8603391
[TBL] [Abstract][Full Text] [Related]
33. Loss of myoepithelial calponin-1 characterizes high-risk ductal carcinoma in situ cases, which are further stratified by T cell composition.
Mitchell E; Jindal S; Chan T; Narasimhan J; Sivagnanam S; Gray E; Chang YH; Weinmann S; Schedin P
Mol Carcinog; 2020 Jul; 59(7):701-712. PubMed ID: 32134153
[TBL] [Abstract][Full Text] [Related]
34. Genetic relation of lobular carcinoma in situ, ductal carcinoma in situ, and associated invasive carcinoma of the breast.
Buerger H; Simon R; Schäfer KL; Diallo R; Littmann R; Poremba C; van Diest PJ; Dockhorn-Dworniczak B; Böcker W
Mol Pathol; 2000 Jun; 53(3):118-21. PubMed ID: 10897329
[TBL] [Abstract][Full Text] [Related]
35. Ductal carcinoma in situ of the breast: immune cell composition according to subtype.
Agahozo MC; van Bockstal MR; Groenendijk FH; van den Bosch TPP; Westenend PJ; van Deurzen CHM
Mod Pathol; 2020 Feb; 33(2):196-205. PubMed ID: 31375764
[TBL] [Abstract][Full Text] [Related]
36. The prognostic significance of immune microenvironment in breast ductal carcinoma in situ.
Toss MS; Abidi A; Lesche D; Joseph C; Mahale S; Saunders H; Kader T; Miligy IM; Green AR; Gorringe KL; Rakha EA
Br J Cancer; 2020 May; 122(10):1496-1506. PubMed ID: 32203210
[TBL] [Abstract][Full Text] [Related]
37. Epidemiologic risk factors for in situ and invasive ductal breast cancer among regularly screened postmenopausal women by grade in the Cancer Prevention Study-II Nutrition Cohort.
Puvanesarajah S; Gapstur SM; Gansler T; Sherman ME; Patel AV; Gaudet MM
Cancer Causes Control; 2020 Jan; 31(1):95-103. PubMed ID: 31802322
[TBL] [Abstract][Full Text] [Related]
38. Ductal carcinoma in situ of the breast: morphological and molecular features implicated in progression.
Carraro DM; Elias EV; Andrade VP
Biosci Rep; 2014 Feb; 34(1):. PubMed ID: 27919043
[TBL] [Abstract][Full Text] [Related]
39. Genetic abnormalities in mammary ductal intraepithelial neoplasia-flat type ("clinging ductal carcinoma in situ"): a simulator of normal mammary epithelium.
Moinfar F; Man YG; Bratthauer GL; Ratschek M; Tavassoli FA
Cancer; 2000 May; 88(9):2072-81. PubMed ID: 10813719
[TBL] [Abstract][Full Text] [Related]
40. Extensive ductal carcinoma In situ with small foci of invasive ductal carcinoma: evidence of genetic resemblance by CGH.
Aubele M; Mattis A; Zitzelsberger H; Walch A; Kremer M; Welzl G; Höfler H; Werner M
Int J Cancer; 2000 Jan; 85(1):82-6. PubMed ID: 10585588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
